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Mathematical models are increasingly being used to compare strategies for tuberculosis (TB) control and inform pol-
icy decisions. Models often do not consider ﬁnancial and other constraints on implementation and may overestimate
the impact that can be achieved. We developed a pragmatic approach for incorporating resource constraints into math-
ematical models of TB. Using a TB transmission model calibrated for South Africa, we estimated the epidemiologic
impact and resource requirements (ﬁnancial, human resource (HR), and diagnostic) of 9 case-ﬁnding interventions.We
compared the model-estimated resources with scenarios of future resource availability and estimated the impact of in-
terventions under these constraints. Without constraints, symptom screening in public health clinics and among per-
sons receiving care for human immunodeﬁciency virus infection was predicted to lead to larger reductions in TB
incidence (9.5% (2.5th–97.5th percentile range (PR), 8.6–12.2) and 14.5% (2.5th–97.5th PR, 12.2–16.3), respectively)
than improved adherence to diagnostic guidelines (2.7%; 2.5th–97.5th PR, 1.6–4.1). However, symptom screening
required large increases in resources, exceeding future HR capacity. Even under our most optimistic HR scenario, the
reduction in TB incidence from clinic symptom screening was 0.2%–0.9%—less than that of improved adherence to
diagnostic guidelines. Ignoring resource constraints may result in incorrect conclusions about an intervention’s impact
andmay lead to suboptimal policy decisions. Models used for decision-making should consider resource constraints.
health resources; mathematical models; South Africa; tuberculosis
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeﬁciency virus; HR, human resources; ICF, intensiﬁed case-
ﬁnding; PR, percentile range; TB, tuberculosis; XTEND, Xpert for Tuberculosis: Evaluating a New Diagnostic; WHO, World Health
Organization.
While South Africa has experienced a decline in tuberculosis
(TB) notiﬁcations from a peak in 2011 (1), TB remains a major
public health problem. In 2017, there were an estimated 322,000
incident cases of TB in South Africa (2) and TB was the leading
infectious cause of death (3). Of the estimated incident cases in
2017, authorities were notiﬁed of fewer than 70%, highlighting
the need for improved TB case-ﬁnding.
Diagnosis of TB in South Africa has traditionally relied on
passive presentation to health-care services, leading to delays in
diagnosis, especially among persons not infected with human
immunodeﬁciency virus (HIV) (4); this suggests that new
approaches are required to identify people with TB sooner. Sev-
eral studies have identiﬁedmissed opportunities for TB screening
in persons already visiting public health clinics (5, 6), and recent
initiatives in South Africa have led to increases in screening of
public health clinic patients. Mathematical modeling (7) has
suggested that increased clinic-based screening, a form of intensi-
ﬁed case-ﬁnding (ICF), could result in signiﬁcant reductions in
TB incidence. However, economic analysis suggests that ICF,
while cost-effective, is likely to require large ﬁnancial commit-
ments (8, 9).
Traditionally, estimates of the impact and cost-effectiveness of
TB case detection (and other interventions) have assumed that
the only constraint on scale-up is the health sector budget.
However, within-sector budgets (e.g., the TB program budget)
may also be constrained if policy-makers are unwilling to
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disinvest in other areas. It is also important to consider con-
straints on human resources (HR) and other health system re-
quirements. Even if funding is available, it may take time to
produce the necessary stafﬁng and infrastructure to deliver ser-
vices. Financial and health systems constraints may limit the
impact of proposed interventions, either because the desired
level of coverage cannot be achieved on the anticipated time
scale or because resources must be reallocated from elsewhere
to achieve it.
While mathematical models are increasingly being used to
predict the impact of TB control strategies and to inform policy-
making, fewmodels include resource constraints. Instead, mod-
els assume some intervention coverage and estimate the costs
and impact of achieving this coverage, assuming sufﬁcient
health system capacity. This issue has recently been highlighted
in HIV modeling, with Mikkelsen et al. (10) calling for new
approaches to dynamically incorporate constraints into mathe-
matical models of the scale-up of antiretroviral therapy (ART).
Lin et al. (11) and Langley et al. (12) have addressed the issue
of health system capacity in TB modeling using an approach
that links detailed epidemiologic and operational models. How-
ever, this approach requires a detailed understanding of the ﬂow
of patients through the health system, and linking the twomodels
has proven technically challenging (12).
We propose an alternative pragmatic approach for incorpo-
rating resource constraints, illustrated via application to ICF for
TB in South Africa. The approach was developed and applied
in the context of informing the South African National Strategic
Plan for HIV, Tuberculosis, and Sexually Transmitted Infec-
tions (13) and was conducted within the tight time frame that
national planning processes allow (14).
Using a dynamic transmission model, secondary data from
costing studies, and national data on health sector HR, we esti-
mated the potential epidemiologic impact and ﬁnancial and
nonﬁnancial resource requirements of achieving prespeciﬁed
coverage targets for 9 ICF interventions. We then estimated
the coverage and impact that could be achieved if resource use
were to remain within estimates of future capacity.
METHODS
Transmissionmodel
The TB transmission model used is similar to a number of
published TB models (15, 16), with additional reﬁnements to
describe screening and diagnosis in South Africa. Full details
are given in Web Appendix 1, Web Tables 1–14, and Web
Figures 1–4 (available at https://academic.oup.com/aje). The
model was used to project the impact of ICF strategies in South
Africa from 2016 to 2035.
In themodel, the population is divided into 3 TB states: suscep-
tible, latently infected, and active disease (stratiﬁed into smear-
positive and smear-negative states). Susceptible persons are
infected at a rate that depends on the prevalence of active dis-
ease. Following infection, some proportion of infected persons
progress directly to active disease; the remainder enter the latent
state. Latently infected persons may remain infected, progress
to disease (reactivation), or be reinfected. Persons with active
disease can self-cure, die, or be diagnosed and treated for TB.
Each of the infection and disease states is further stratiﬁed by
treatment history (previously treated or treatment-naive) and
drug resistance status (susceptible or multiple-drug-resistant).
The model includes HIV infection status and the associa-
tion of coinfection with the risk of developing and dying from
TB. Age-speciﬁc HIV incidence and ART coverage are exter-
nal inputs to the model. The HIV-infected population is strati-
ﬁed by CD4 cell count and time on ART. ART is assumed to
reduce the risk of developing TB and the risks of HIV- and
TB-associated mortality.
Screening, diagnosis, and treatment are a simpliﬁcation
of the national TB diagnostic guidelines in South Africa (17)
(Web Figures 2 and 3). These are not included as explicit states
in the model. Instead we calculate the rate at which people start
treatment based on the steps of the diagnostic pathway (see
WebAppendix 1 for details).
Base case and interventions
The base case described continuation of current TB care in
South Africa. We assumed that people self-presented (passively)
with symptoms suggestive of TB at rates estimated by ﬁtting the
model to incidence and notiﬁcation data from the period prior
to the introduction of ICF. We estimated current rates of ICF
(among clinic patients and HIV-infected persons enrolled in
care) by ﬁtting the model to the total reported number of persons
screened for TB in recent years. Among persons not receiving
HIV care, we assumed that those presenting with prolonged
cough (of more than 2 weeks) were referred for sputum testing
(17), while those in HIV care were evaluated on the basis of the
presence of any TB symptoms (using theWorld Health Organi-
zation (WHO) screening tool). On the basis of data reported to
WHO, we assumed that 40% of persons enrolled in HIV care
had been asked about TB symptoms at their last visit (18).
National guidelines also recommend that household contacts of
TB cases be screened for TB. We assumed that visits by con-
tacts to TB screening clinics were captured in the baseline pas-
sive screening rate. Active contact investigations involving
household visits are not widely implemented in South Africa
and were not included in the model.
Eighty percent of initial diagnostic tests were assumed to
be carried out via the Xpert MTB/RIF assay (Cepheid Inc.,
Sunnyvale, California), which detects Mycobacterium tubercu-
losis (MTB) complex and rifampin (RIF) resistance, with the
remainder being conducted via smear microscopy (13). Xpert
is a nucleic acid ampliﬁcation test that was endorsed byWHO
in 2013 and subsequently adopted as the initial test for TB
diagnosis in South Africa. HIV-infected persons with a nega-
tive Xpert test result should have further sputum samples col-
lected for culture and drug susceptibility testing, in line with
national guidelines (17). However, on the basis of data from the
Xpert for Tuberculosis: Evaluating a New Diagnostic (XTEND)
Study, we assumed that only 14% of patients received appropri-
ate follow-up (19). On the basis of a systematic review published
in 2014 (20) and data from the XTENDStudy (21), we assumed
pretreatment loss to follow-up of 17%. Historical values for
treatment success were based on national treatment outcome
data: 78% for drug-susceptible TB and 50% for multiple-
drug-resistant TB in 2015 (22). Full details on the base-case
assumptions can be found inWeb Appendix 1.
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In a secondary analysis, we adapted the base case to include
the following activities, planned in South Africa as part of the
National Strategic Plan for HIV, Tuberculosis, and Sexually
Transmitted Infections (13): reducing pretreatment loss to
follow-up by 80% (from 17% to 4%) by 2021 and introduc-
ing short-course multiple-drug-resistant TB treatment (23)
alongside continued use of bedaquiline for pre–extensively
drug-resistant and extensively drug-resistant TB (24). This
analysis allowed us to explore how the impact and resource
use of the ICF strategies may be altered by other future im-
provements in the TB program.
We considered 9 interventions representing increased adher-
ence to current diagnostic guidelines and various strategies for
ICF. These were deﬁned in collaboration with policy-makers as
part of the South African TB Think Tank Project (14) and are
shown in Table 1. For all interventions, we assumed linear scale-
up to the target values between 2017 and 2021.
Resource requirements and constraints
To illustrate our approach, we considered 3 types of resources
and their future constraints: budget (total costs of the TB pro-
gram), HR (amount of nurse time spent on TB activities), and
diagnostic (ratio of number of Xpert tests to number of TB notiﬁ-
cations). Thesewere identiﬁed throughdiscussionswith local stake-
holders that took place as part of the SouthAfrican TBThink Tank
Project (14). During these discussions, stakeholders from the
South African National Department of Health highlighted
Table 1. Summary of the Interventions included in amodel of tuberuculosis transmission, South Africa, 2016–2035a
Intervention Description
1. Base case Continuation of current practice
2. Xpertb testing Use of Xpert as the ﬁrst-line test is increased from 80% to 100%.
3. Guidelines Adherence to Xpert-negative guidelines is increased from 14% to 90% in persons known
to be infected with HIV.
4. 2 + 3 Combination of interventions 2 and 3
5. Cough HIV+ Cough-based screening (compared withWHO symptom screening in the base case) in
100% (compared with 40% in the base case) of HIV-infected persons enrolled in care
6. Cough PHC Cough-based screening in 90% (compared with 50% in the base case) of PHC patients
7. SymptomHIV+ WHO symptom screening in 100% (compared with 40% in the base case) of HIV-
infected persons enrolled in care
8. SymptomPHC WHO symptom screening (compared with cough-based screening in the base case) in
90% (compared with 50% in the base case) of PHC clinic patients
9. 4 + 6 Combination of interventions 2, 3, and 6
10. 4 + 8 Combination of interventions 2, 3, and 8
Abbreviations: HIV, human immunodeﬁciency virus; HIV+, human immunodeﬁciency virus–positive; MTB,Myco-
bacterium tuberculosis; PHC, public health clinic; RIF, rifampin;WHO,World Health Organization.
a Interventions were scaled up linearly from 2017.
b Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, California).
Table 2. Resource Constraints Applied in a Model of Tuberculosis Transmission, South Africa, 2016–2035
Type of Constraint
Constraint Scenarioa
Low Medium High
Budget (total cost of
TB program)
GDP growth Low scenario plus reprioritization
based on disease burden from
2017 to 2021
Medium scenario plus
earmarked taxes
from 2017 to 2021
HR (amount of nurse time
spent on TB activities)
Population
growth
Low scenario plus reprioritization
based on disease burden from
2017 to 2021
Medium scenario plus
historical growth in
nursing workforce
Diagnosticb (ratio of no. of
Xpertc tests to no. of TB
notiﬁcations)
Xpert test:
notiﬁcation
ratio does not
exceed 20:1
Xpert test:notiﬁcation ratio does not
exceed 20:1
Xpert test:notiﬁcation
ratio does not
exceed 20:1
Abbreviations: GDP, gross domestic product; HR, human resources; MTB,Mycobacterium tuberculosis; RIF, rifampin;
TB, tuberculosis.
a The low scenario is the most restrictive; the high scenario is the least restrictive.
b A single diagnostic constraint scenario was considered.
c Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, California).
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ﬁnancial, HR, and diagnostic supplies constraints as critical
areas to be addressed in this analysis. Full details on the meth-
ods used to estimate unit costs and nurse time and the deriva-
tion of the future constraints can be found elsewhere (25).
Three future scenarios for the budget and total nurse time
were considered (Table 2). We refer to these as the low (most
restrictive), medium, and high (least restrictive) scenarios;
further details are provided below. For the diagnostic con-
straint, we considered a single scenario in which the ratio of
Xpert tests to TB notiﬁcations was capped at 20:1. This con-
straint reﬂects a limit on diagnostic supplies (Xpert cartridges)
purchased annually in South Africa. The ratio was set follow-
ing discussion with the South African National Department of
Health.
The low-budget (most restrictive) scenario was based on pre-
dicted gross domestic product growth of 1.7% per year (26).
The medium scenario additionally assumed that a proportion of
the current budget was reallocated to TB in line with the propor-
tion of deaths in South Africa attributable to TB (approximately
10%–15%), and the high scenario assumed that a proportion of
a health budget that achieved its full ﬁscal space growth was
similarly reallocated.
In the low-HR scenario, the number of nurse minutes spent
on TB was adjusted in future years on the basis of population
growth only. The medium constraint incorporated a realloca-
tion of the current workforce to TB on the basis of disease bur-
den, as above; and the high scenario similarly reallocated a
proportion of the nursing workforce that achieved its maxi-
mum growth on the basis of historical growth rates.
The budget and nurse time required in the base case and in
each intervention were calculated by multiplying unit costs and
minutes of nurse time per activity by the outputs of the trans-
mission model (Table 3). Use of Xpert testing was calculated
by dividing the number of tests (an output of the model) by the
model-estimated number of notiﬁcations.
The total costs, nurse time, and Xpert test:TB notiﬁcation
ratio required by each interventionwere comparedwith the con-
straint scenarios to identify interventions that exceeded the con-
straints. These interventions were then resimulated to estimate
the epidemiologic impact under the constrained scenarios. For
the budget and HR constraints, we iteratively reduced the maxi-
mum intervention coverage achieved in 2021 (assuming linear
scale-up from 2017, as in the unconstrained scenario) such that
the projected cost or nurse time remained below the constraint
over the entire time horizon (2017–2035). When implementing
the constraint on the Xpert test:TB notiﬁcation ratio, we assumed
that an intervention would be stopped (coverage reduced to zero)
when the 20:1 ratio suggested by the National Department of
Health was exceeded.
Model calibration
The model was ﬁtted to TB notiﬁcation data (total and mul-
tiple-drug-resistant) (18), the number of screenings reported to
the National Department of Health, the number of laboratory
tests conducted (27), and estimated TB incidence and mortal-
ity (1). Details can be found in Web Appendix 2 and Web
Table 15. In summary, values for parameters were sampled
Table 3. Amounts of Required Nurse Time and Costs of Various Tuberculosis Control Activities, per Unit of Activity,
South Africa, 2016
Activity Nurse Time, minutes Cost, $US Unit of Activity
Passive screening 2.63 0.68 Per screen
Cough screening 1.26 0.68 Per screen
WHO symptom screening 4.00 1.36 Per screen
Sputum smear microscopy 3.16 10.87 Per screen
Xperta testing 3.16 32.24 Per screen
Follow-up of Xpert-negative persons 8.61 24.00 Per screen
First-line treatment (initiation phase, 2 months) 35.72 21.43 Per monthb
First-line treatment (continuation phase, 4months) 7.57 21.43 Per monthb
MDR treatment, DOT (initiation phase, 6 months) 237.04 359.10 Per monthb,c
MDR treatment, non-DOT (initiation phase, 6 months) 84.47 359.10 Per monthb,c
MDR treatment, DOT (continuation phase, 18months) 159.83 359.10 Per monthb
MDR treatment, non-DOT (continuation phase, 18months) 84.47 359.10 Per monthb
Isoniazid preventive therapy 5.54 7.81 Per month
Abbreviations: DOT, directly observed therapy; MDR, multiple-drug-resistant; MTB,Mycobacterium tuberculosis;
RIF, rifampin;WHO,World Health Organization.
a Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, California).
b On the basis of discussion with the South African National Department of Health, we assumed that 20% of drug-
susceptible patients and 20% of decentralized MDR patients receive treatment via DOT; the remainder only visit
clinics monthly to obtain antituberculosis medication.
c Sixty percent of MDR patients are hospitalized during the intensive phase. This activity is not included in our esti-
mates of public health clinic nurse time.
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from prior speciﬁed ranges. The model was then calibrated in a
2-step process by varying selected model parameters to mini-
mize the weighted sum of squared differences between the
model and the observed data. First, the contact rate and passive
screening rate were varied to match the incidence and notiﬁca-
tions in 1990 (before the increase in HIV-associated TB). Sec-
ondly, the increase in passive screening, the rate of ICF, the rate
of acquisition of drug resistance, a multiplier for the impact of
ART onTB risk among people livingwithHIV, and amultiplier
for the TBmortality rate in HIV-infected persons were varied to
ﬁt the model to all calibration data from 1990 to 2015. This pro-
cess was repeated 1,000 times to incorporate the uncertainty in
the unﬁtted parameters.
RESULTS
Baseline ﬁt and base-case projection
The model reproduces the trends in TB incidence, mortality,
and notiﬁcations and predicts continued declines in incidence
and mortality up to 2020 (Figure 1). Future notiﬁcations remain
largely constant, although with large uncertainty. Short-term in-
creases in notiﬁcations result from an increase in the number of
true-positive TB cases diagnosed. However, the model indicates
that over time, as TB incidence falls, there will be an increasing
number of false-positive notiﬁcations due to the imperfect speci-
ﬁcity of the diagnostic process. Reported testing volumes
are within the model uncertainty. Baseline estimates of the total
cost and nurse minutes spent on TB activities (see Figure 2) in
2015/2016 are consistent with previous estimates (25).
Total costs, nurse minutes, and the ratio of Xpert tests to TB
notiﬁcations are predicted to increase over time. The increases
in costs and nurse time are driven by population growth and
increased access to HIV care, both of which result in increased
numbers of people being screened for TB. The increase in the
Xpert test:notiﬁcation ratio is driven by the fall in the preva-
lence of TB; as TB becomes rarer, the number of persons who
will have to be tested in order to ﬁnd 1 TB case will increase.
Impact of interventions—unconstrained scenario
In the base case (which includes current levels of ICF), the
predicted reduction in TB incidence from 2016 to 2035 is
18.9% (2.5th–97.5th percentile range (PR), 3.5–29.4). Figure 3
and Table 4 show the additional percentage change in the inci-
dence rate in 2035 compared with the base case (intervention 1)
for each intervention. When not accounting for con-
straints (darkest bars), the largest reductions in incidence are
predicted for interventions which include increased screening
coverage using the WHO symptom tool (interventions 8
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Figure 1. Baseline ﬁt of a tuberculosis (TB) transmission model to TB data from South Africa, 2016–2035. A) TB incidence per 100,000 popula-
tion, overall (dark gray) and among persons positive for human immunodeﬁciency virus (HIV+) (light gray). The dotted line shows the point value,
and the shaded area shows the range of the World Health Organization estimate. The dashed line shows the median value, and the solid lines
show the range of the model output. B) TBmortality per 100,000 population in HIV-uninfected persons (HIV−; dark gray) and people living with HIV
(HIV+; light gray). Other details are the same as those for panel A. C) Numbers of TB notiﬁcations (in thousands) for all forms of TB (circles) and
multiple-drug-resistant (MDR) TB (triangles). Points show the reported data. The dashed line shows the median value, and the solid lines show the
range of themodel output. D) Rate of laboratory testing for TB per 100,000 population. Other details as the same as those for panel C.
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(9.5%; 2.5th–97.5th PR, 8.6–12.2), 10 (12.6%; 2.5th–97.5th
PR, 9.8–14.9), and 7 (14.5%; 2.5th–97.5th PR, 12.2–16.3),
in order of increasing impact). A smaller but signiﬁcant
reduction (5.0%; 2.5th–97.5th PR, 3.8–7.1) is also predicted
for increased use of cough-based screening in public health
clinic patients when combined with improved adherence to
the diagnostic algorithm (intervention 9).
Increased utilization of Xpert testing (intervention 2) and
improved adherence to diagnostic guidelines among persons
with negative Xpert assay results (intervention 3) produce
small reductions in incidence. However, the combination of
these two strategies (intervention 4) produces an impact similar
to that of increases in public health clinic screening (intervention
6). The change to cough-based screening among persons receiv-
ing HIV care (intervention 5), which is not recommended in the
national orWHO guidelines, results in an increase in incidence
compared with the base case. This is because cough-based
screening has lower sensitivity than the WHO screening
algorithm, which is included in the base case. As a result,
despite the assumed increase in coverage, this intervention
strategy is inferior to continuation of current practice.
Resource requirements
Figure 2 shows the predicted resources required for the
base case and each intervention from 2016 to 2035.
All interventions, including the base case, exceed the low
budget and low nurse time constraints (the most restrictive
scenarios); these scenarios were not considered further. In
contrast, the medium and high budget constraints are not ex-
ceeded by any intervention. For interventions 6–10, which
include increases in ICF, the model predicts increases in
nurse time which exceed the proposed constraints. This is
particularly the case for interventions based on WHO symp-
tom screening (interventions 7, 8, and 10) because of the
increased amount of time taken to carry out the screening and
the lower speciﬁcity as compared with cough screening, which
results in an increased number of tests being administered in
persons without TB. The Xpert constraint is exceeded by inter-
ventions that include increased use of symptom screening (in-
terventions 7, 8, and 10) and strategies that include increased
use of Xpert as the ﬁrst-line test (interventions 2, 4, and 9).
The most ambitious intervention (intervention 10) requires
more than 45 Xpert tests per TB notiﬁcation.
Impact of interventions—constrained scenarios
Inclusion ofmediumbudget constraints in themodel (Figure 3,
dark gray bars) does not change the predicted impact, because
the future budget predictions do not exceed these constraints.
The high budget constraint is also not exceeded (not shown).
Similarly, the impact in the base case (intervention 1), strategies
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Figure 2. Model projection of future costs, human resource requirements, and Xpert test:tuberculosis (TB) notiﬁcation ratio (ratio of number of Xpert
tests (Xpert MTB/RIF assay; Cepheid Inc., Sunnyvale, California) to number of TB notiﬁcations) of the TB control program in South Africa, 2016–2035.
Symbols show the median model prediction for each intervention from 2016 to 2035. A) Total costs of TB control activities, in millions of US dollars;
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focused on improved adherence to guidelines (interventions 2–4),
and the use of cough screening in HIV-infected persons (inter-
vention 5) are not affected by the nurse time constraint.
Both high (Figure 3,mediumgray bars) andmedium (Figure 3,
light gray bars) HR constraints reduce the impact of increased
ICF (interventions 6–10), because the previously assumed cover-
age (see Table 1) cannot be reached.Under the highHR constraint,
the largest median impact is still observed for increased symptom
screening of HIV-infected persons (intervention 7). However, for
the medium HR constraint, the ranking of the interventions is
changed, with the largest impacts predicted for increased adher-
ence to guidelines (intervention 4) and the combination with
increased cough screening in clinic patients (intervention 9).
The additional effect of the Xpert constraint on top of the
medium HR constraint (Figure 3, white bars) is small, partly
because much of the impact in each intervention has been
achieved by the point at which the Xpert test:notiﬁcation
ratio exceeds 20:1.
Secondary analysis
The results for the secondary analysis including strategy out-
lined in the National Strategic Plan for HIV, Tuberculosis, and
Sexually Transmitted Infections are qualitatively the same. In
the base case, the model predicts a greater reduction in inci-
dence due to the additional impact of improved linkage to care.
However, the incremental beneﬁt of each intervention, when
combined with reduced pretreatment loss to follow-up, is smaller
since the impacts are not additive. The overall costs and nurse
time are lower in the National Strategic Plan scenario than for the
corresponding interventions in the primary analysis; however, the
same interventions exceed the constraints. Web Appendix 3 and
Table 4. Reductions in Tuberculosis Incidence Predicted by a
Tuberculosis TransmissionModel, South Africa, 2016–2035
Interventiona Median (2.5th–97.5th PR)Reduction in TB Incidence, %b
1. Base case 0 (0–0)
2. Xpertc testing 1.6 (0.9–2.4)
3. Guidelines 1.1 (0.6–1.6)
4. 2 + 3 2.7 (1.6–4.1)
5. Cough HIV+ −0.7 (−2.0–0.76)
6. Cough PHC 2.6 (2.1–3.2)
7. SymptomHIV+ 14.5 (12.2–16.3)
8. SymptomPHC 9.5 (8.6–12.2)
9. 4 + 6 5.0 (3.8–7.1)
10. 4 + 8 12.6 (9.8–14.9)
Abbreviations: HIV+, human immunodeﬁciency virus–positive; MTB,
Mycobacterium tuberculosis; PHC, public health clinic; PR, percentile
range; RIF, rifampin; TB, tuberculosis.
a Numbers refer to the interventions listed in Table 1.
b Values indicate the predictedmedian percent reduction in TB inci-
dence in 2035 in the intervention group compared with the base case
(intervention 1).
c Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, California).
–10
0
10
20
30
2 3 4 5 6 7 8 9 10
Intervention No.
R
ed
uc
tio
n 
in
 In
ci
de
nc
e 
R
at
e,
 %
Unconstrained
Medium Budget
High HR 
Medium HR
Medium HR + Diagnostic
Figure 3. Reductions in tuberculosis (TB) incidence predicted by a TB transmissionmodel, South Africa, 2016–2035. The graph shows the percent-
age reduction in the TB incidence rate in 2035 as compared with baseline in 2035 (intervention 1). Shading indicates the type of constraint applied to
the model. Boxes show the 25th–75th percentile range, whiskers indicate 1.5 times the interquartile range, and black circles show outliers. The high
(least restrictive) budget constraint is not shown because results were the same as those for the medium budget constraint. Values above 0 (dashed
horizontal line) indicate a larger reduction in TB incidence as compared with baseline. HR, human resources.
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Web Figures 5–7 provide further details on the results of the sec-
ondary analysis.
DISCUSSION
Our results show that ICF may result in signiﬁcant reductions
in TB incidence, but with large increases in ﬁnancial and HR re-
quirements.While the costs may remain below the assumed bud-
get projections, ICF strategies may exceed HR capacity, even
under optimistic scenarios of reallocation of nurse time to TB
and normative limits around Xpert test numbers. When the HR
constraint is included in the model, the ranking of interventions
by impact is changed. In particular, the impact of ICF strategies
is greatly reduced and those strategies may, in rare cases, be
less effective than continuation of current practice.
Our approach was developed and implemented in the context
of supporting the use of modeling to inform TB control policy in
South Africa (14). Our aim was to demonstrate the feasibility of
a simple approach to highlight the potential importance of con-
straints. In this light, several simplifying assumptions weremade.
When incorporating constraints, we assumed that other TB con-
trol activities would continue at their current levels and that the
coverage of the new intervention would be reduced to satisfy the
constraint. An alternative would be to consider that the full inter-
vention coverage is reached and that the capacity for other activi-
ties must be reduced to compensate. This approach could be
considered in the framework used here but would require
rules for prioritization of activities.
Our illustrative approach also assumed a single change to
intervention coverage to satisfy the constraints over the entire
time period considered. In reality, the mixture and coverage of
interventions may change over time as capacity varies. In our
example, the HR constraint was typically exceeded in the short
term before the HR capacity could be increased. As such, it is
possible that coverage could subsequently be increased in the
future. Our results are therefore probably a conservative estimate
of the impact that could be achieved under these constraints.
Yaesoubi and Cohen (28) modeled dynamic case-ﬁnding poli-
cies and showed that they were preferable to static policies.
However, they only considered the ﬁnancial requirements of
those policies. Combining these two approaches may be a use-
ful way to identify strategies that account for the time scales of
staff recruitment.
Several studies have addressed the issue of resource con-
straints in infectious disease models. Lin et al. (11) proposed an
alternative approach with which to incorporate health system
capacity in models by combining a discrete event simulation of
the health systemwith a compartmental model of TB transmis-
sion. This approach has been used successfully to explore
the impact of new diagnostics in Tanzania (12); however, it re-
quires a detailed understanding of the whole health system in
a country and presents computational demands in linking
the models. Hontelez et al. (29) incorporated constraints into
their analysis of changes to HIV treatment eligibility by deﬁn-
ing a priori a set of treatment scale-up scenarios that represented
potential supply- and demand-side constraints. In contrast, our
approach is similar to the AsiaFluCap Simulator used in the
planning of pandemic inﬂuenza control (30); the outputs of
the model are used to dynamically estimate the resource
needs of different interventions and compare these with con-
straints deﬁned using a combination of secondary data and
policy-maker consultation.
While we attempted to include the key aspects of TB con-
trol in South Africa, there were several important limitations.
We relied on routinely collected data, which may be subject to
inaccuracy and bias. We assumed that ICF occurs indepen-
dently of true TB status and hence may underestimate the TB
prevalence in the population screened and the ICF impact. We
also assumed that linkage to TB treatment and completion of
treatment are equal in persons identiﬁed passively and persons
identiﬁed via ICF. If those identiﬁed via ICF are less likely to
start treatment (31), the model may overestimate the impact
and resource use of the ICF interventions. It is also possible
that linkage to TB treatment may be greater for people receiv-
ing HIV care than for people not engaged with the health sys-
tem. If this were the case, it might increase the relative impact
of screening among people living with HIV as compared with
other forms of ICF.
In this work, we considered South Africa as a whole. The
resource requirements of ICF could be reduced by targeting in-
terventions toward geographical regions with the highest bur-
den. The preferred strategies may differ between areas because
of differences in factors such as the prevalence of HIV
coinfection.
The model includes the association between HIV infection
and risk of TB but does not currently include other known risk
factors for TB, such as diabetes or smoking. Strategies for de-
tecting and preventing TB in these risk groups may form an im-
portant part of future efforts to control TB in South Africa.
Strategies that target these and other risk groups may reduce
the resource requirements of case-ﬁnding interventions.
Our results can be used to illustrate to policy-makers the need
to deﬁne policies that expand TB services at the same time as
they address constraints to expansion. For example, in this work
we assumed that all activities were conducted by nurses, the
main cadre of staff that have historically been responsible for
delivering TB services in South Africa. Our ﬁndings show that
policies which aim to increase TB screening must be accompa-
nied by strategies to address HR constraints, via investment in
training or by task-shifting activities like contact tracing or
symptom screening to other staff, such as lay workers. While
none of the interventions exceeded themedium and high budget
constraints, the constraint scenarios assume a substantial reallo-
cation of the health budget. Without this reallocation, none of
the interventions are feasible. Limiting use of Xpert testing
based on the number needed to test to diagnose 1 TB case may
also restrict the reduction in incidence that can be achieved. As
TB burden declines, this ratio will need to increase to ensure
that cases are not missed.
It is also important to consider how these resource constraints
may affect the cost-effectiveness of different strategies. Strate-
gies that are deemed cost-effective in the absence of constraints
may not be cost-effective if the potential impact is limited by
constraints or the costs of relaxing constraints are included in
the analysis. This is the focus of ongoing research.
In conclusion, this work highlights the importance of includ-
ing resource constraints in models used to evaluate TB control
strategies. Ignoring these constraints may result in overestima-
tion of the achievable impact of interventions in the absence of
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other actions to increase health system capacity, and ultimately
may lead to inappropriate or unwarranted policy decisions.
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